Martin Anne Rijlaarsdam

Martin Anne Rijlaarsdam

Auto-generated profile, based on publicly available information

Martin Anne Rijlaarsdam

Department of Pathology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2015 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MMMatthew J Murray
Matthew J Murray
EBEmma Bell
Emma Bell
KRKatie L Raby
Katie L Raby
MRMartin A Rijlaarsdam
Martin A Rijlaarsdam
AGAd J M Gillis
Ad J M Gillis
NCNicholas Coleman
Nicholas Coleman
The current biomarkers alpha-fetoprotein and human chorionic gonadotropin have limited sensitivity and specificity for diagnosing malignant germ-cell tumours (GCTs). MicroRNAs (miRNAs) from the miR–371–373 and miR–302/367 clusters are overexpressed in all malignant GCTs, and some of these miRNAs show elevated serum levels at diagnosis. Here, we developed a robust technical pipeline to quantify these miRNAs in the serum and cerebrospinal fluid (CSF). The pipeline was used in samples from a cohort of exclusively paediatric patients with gonadal and extragonadal malignant GCTs, compared with appropriate tumour and non-tumour control groups. We developed a method for miRNA quantification that enabled sample adequacy assessment and reliable data normalisation. We performed qRT–PCR profiling for miR–371–373 and miR–302/367 cluster miRNAs in a total of 45 serum and CSF samples, obtained from 25 paediatric patients. The exogenous non-human spike-in cel–miR–39–3p and the endogenous housekeeper miR–30b–5p were optimal for obtaining robust serum and CSF qRT–PCR quantification. A four-serum miRNA panel (miR–371a–3p, miR–372–3p, miR–373–3p and miR–367–3p): (i) showed high sensitivity/specificity for diagnosing paediatric extracranial malignant GCT; (ii) allowed early detection of relapse of a testicular mixed malignant GCT; and (iii) distinguished intracranial malignant GCT from intracranial non-GCT tumours at diagnosis, using CSF and serum samples. The pipeline we have developed is robust, scalable and transferable. It potentially promises to improve clinical management of paediatric (and adult) malignant GCTs.

20 August 2013 in Molecular Oncology
Verified
Journal Article
Open access
AGAd J.M. Gillis
Ad J.M. Gillis
MRMartin A. Rijlaarsdam
Martin A. Rijlaarsdam
RERonak Eini
Ronak Eini
LDLambert C.J. Dorssers
Lambert C.J. Dorssers
KBKatharina Biermann
Katharina Biermann
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
Germ cell cancers (GCC) are the most frequent malignancy in young Caucasian males. GCC can consist of seminomas (SE) and non‐seminomas (malignant NS: embryonal carcinoma (EC), yolk sac tumor (YS), choriocarcinoma (CH) and teratoma (TE)). Current serum‐markers used for diagnosis and follow‐up (AFP, hCG) are predominantly related to YS and CH and marker positivity can vary during disease. Therefore, stable markers consistently identifying more GCC components, specifically the stem cell components SE and EC, are of interest. Expression of the embryonic stem cell miR‐371‐3 and miR‐302/367 clusters in SE/EC/YS suggest possible application of these micro‐RNAs as GCC tumor‐markers. The TSmiR protocol constitutes a complete, quality‐controlled pipeline for the detection of miRs in serum, based on magnetic bead‐based purification and qPCR quantification. As a proof of principle, TSmiR was applied to five independent serum sample series including 80 GCCs, 47 controls, 11 matched pre/post orchidectomy samples and 12 no‐GCC testicular masses. GCC serum samples showed a consistent, significant (p < 0.0064) increase of miR‐371/372/373/367 levels. Analogous, serum levels returned to baseline after orchidectomy (stage‐I disease). Moreover, there was a trend toward higher miR levels in patients with metastasis. These results imply suitability for diagnosis and follow‐up. TSmiR showed an overall sensitivity of 98%, clearly outperforming the traditional serum markers AFP/hCG (36%/57%, sensitivityAFP = 3%/45%; sensitivityhCG = 62%/66%, SE/NS). TSmiR misclassified one tumor as a control. Serum AFP/hCG and TSmiR combined identified all T samples correctly. In conclusion, TSmiR constitutes a highly sensitive and reproducible serum test for GCC patients, suitable to be prospectively tested for diagnostic and follow‐up purposes.

10 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMartin A Rijlaarsdam
Martin A Rijlaarsdam
DTDavid M J Tax
David M J Tax
AGAd J M Gillis
Ad J M Gillis
LDLambert C J Dorssers
Lambert C J Dorssers
DKDevin C Koestler
Devin C Koestler
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
The cell of origin of the five subtypes (I-V) of germ cell tumors (GCTs) are assumed to be germ cells from different maturation stages. This is (potentially) reflected in their methylation status as fetal maturing primordial germ cells are globally demethylated during migration from the yolk sac to the gonad. Imprinted regions are erased in the gonad and later become uniparentally imprinted according to fetal sex. Here, 91 GCTs (type I-IV) and four cell lines were profiled (Illumina’s HumanMethylation450BeadChip). Data was pre-processed controlling for cross hybridization, SNPs, detection rate, probe-type bias and batch effects. The annotation was extended, covering snRNAs/microRNAs, repeat elements and imprinted regions. A Hidden Markov Model-based genome segmentation was devised to identify differentially methylated genomic regions. Methylation profiles allowed for separation of clusters of non-seminomas (type II), seminomas/dysgerminomas (type II), spermatocytic seminomas (type III) and teratomas/dermoid cysts (type I/IV). The seminomas, dysgerminomas and spermatocytic seminomas were globally hypomethylated, in line with previous reports and their demethylated precursor. Differential methylation and imprinting status between subtypes reflected their presumed cell of origin. Ovarian type I teratomas and dermoid cysts showed (partial) sex specific uniparental maternal imprinting. The spermatocytic seminomas showed uniparental paternal imprinting while testicular teratomas exhibited partial imprinting erasure. Somatic imprinting in type II GCTs might indicate a cell of origin after global demethylation but before imprinting erasure. This is earlier than previously described, but agrees with the totipotent/embryonic stem cell like potential of type II GCTs and their rare extra-gonadal localization. The results support the common origin of the type I teratomas and show strong similarity between ovarian type I teratomas and dermoid cysts. In conclusion, we identified specific and global methylation differences between GCT subtypes, providing insight into their developmental timing and underlying developmental biology. Data and extended annotation are deposited at GEO (GSE58538 and GPL18809).

16 August 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MRM A Rijlaarsdam
M A Rijlaarsdam
HHH A D M van Herk
H A D M van Herk
AGA J M Gillis
A J M Gillis
HSH Stoop
H Stoop
GJG Jenster
G Jenster
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
OCT3/4 (POU5F1) is an established diagnostic immunohistochemical marker for specific histological variants of human malignant germ cell tumours (GCTs), including the seminomatous types and the stem cell component of non-seminomas, known as embryonal carcinoma. OCT3/4 is crucial for the regulation of pluripotency and the self-renewal of normal embryonic stem- and germ cells. Detection of expression of this transcription factor is complicated by the existence of multiple pseudogenes and isoforms. Various claims have been made about OCT3/4 expression in non-GCTs, possibly related to using nonspecific detection methods. False-positive findings undermine the applicability of OCT3/4 as a specific diagnostic tool in a clinical setting. In addition, false-positive findings could result in misinterpretation of pluripotency regulation in solid somatic cancers and their stem cells. Of the three identified isoforms – OCT4A, OCT4B and OCT4B1 – only OCT4A proved to regulate pluripotency. Up until now, no convincing nuclear OCT4A protein expression has been shown in somatic cancers or tissues. This study investigates expression of the various OCT3/4 isoforms in GCTs (both differentiated and undifferentiated) and somatic (non-germ cell) cancers, including representative cell lines and xenografts. Using specific methods, OCT4A and OCT4B1 are shown to be preferentially expressed in undifferentiated GCTs. The OCT4B variant shows no difference in expression between GCTs (either differentiated or undifferentiated) and somatic cancers. In spite of the presence of OCT4A mRNA in somatic cancer-derived cell lines, no OCT3/4 protein is detected. Significant positive correlations between all isoforms of OCT3/4 were identified in both tumours with and without a known stem cell component, possibly indicating synergistic roles of these isoforms. This study confirms that OCT4A protein only appears in seminomatous GCTs, embryonal carcinoma and representative cell lines. Furthermore, it emphasises that in order to correctly assess the presence of functional OCT3/4, both isoform specific mRNA and protein detection are required.

1 December 2014 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
MRMartin A. Rijlaarsdam
Martin A. Rijlaarsdam
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga

7 November 2014 in Andrology
Verified
Journal Article
Open access
PDF file
MRM. A. Rijlaarsdam
M. A. Rijlaarsdam
TAT. van Agthoven
T. van Agthoven
AGA. J. M. Gillis
A. J. M. Gillis
SPS. Patel
S. Patel
KHK. Hayashibara
K. Hayashibara
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
Summary: microRNAs (miRs) are short non‐coding RNA molecules (≈21 nucleotides) involved in regulation of translation. As such they are crucial for normal cell development and differentiation as well as cellular maintenance. Dysregulation of miRs has been reported in various diseases, including cancer. Interestingly, miRs can be informative as tumor classifiers and disease biomarkers. Recent studies demonstrated the presence of miRs in body fluids like serum, thus providing a putative non‐invasive tool to study and monitor disease state. Earlier targeted studies by several independent groups identified specific embryonic miRs as characteristic for germ cell tumors (GCT) (miR‐371‐2‐3 & miR‐302/367 clusters). This study reports a high‐throughput miR profiling (≈750 miRs) approach on serum from testicular germ cell tumor patients (14 seminoma and 10 non‐seminoma) and controls (n = 11), aiming at independent identification of miRs as candidate biomarkers for testicular GCT. A magnetic bead capture system was used to isolate miRs from serum. Subsequently, the TaqMan Array Card 3.0 platform was used for profiling. The previously identified miRs 371 and 372 were confirmed to be specifically elevated in serum from germ cell tumor patients. In addition, several novels miRs were identified that were discriminative between germ cell cancer and controls: miR‐511, ‐26b, ‐769, ‐23a, ‐106b, ‐365, ‐598, ‐340, and let‐7a. In conclusion, this study validates the power of the embryonic miRs 371 and 372 in detecting malignant GCT (SE and NS) based on serum miR levels and identifies several potential novel miR targets.